
Hilkka Soininen

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3729551/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-1458.	9.4	3,741
2	A 2 year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomised controlled trial. Lancet, The, 2015, 385, 2255-2263.	6.3	2,307
3	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nature Genetics, 2019, 51, 414-430.	9.4	1,962
4	Midlife vascular risk factors and Alzheimer's disease in later life: longitudinal, population based study. BMJ: British Medical Journal, 2001, 322, 1447-1451.	2.4	1,298
5	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. JAMA - Journal of the American Medical Association, 2015, 313, 1924.	3.8	1,166
6	Risk score for the prediction of dementia risk in 20 years among middle aged people: a longitudinal, population-based study. Lancet Neurology, The, 2006, 5, 735-741.	4.9	822
7	Rare coding variants in PLCG2, ABI3, and TREM2 implicate microglial-mediated innate immunity in Alzheimer's disease. Nature Genetics, 2017, 49, 1373-1384.	9.4	783
8	Common genetic variants influence human subcortical brain structures. Nature, 2015, 520, 224-229.	13.7	772
9	New insights into the genetic etiology of Alzheimer's disease and related dementias. Nature Genetics, 2022, 54, 412-436.	9.4	700
10	The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER): Study design and progress. Alzheimer's and Dementia, 2013, 9, 657-665.	0.4	385
11	Duration of preclinical, prodromal, and dementia stages of Alzheimer's disease in relation to age, sex, and <i>APOE</i> genotype. Alzheimer's and Dementia, 2019, 15, 888-898.	0.4	290
12	Apolipoprotein E É>4 magnifies lifestyle risks for dementia: a populationâ€based study. Journal of Cellular and Molecular Medicine, 2008, 12, 2762-2771.	1.6	287
13	Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain, 2015, 138, 1327-1338.	3.7	284
14	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. Nature Genetics, 2015, 47, 445-447.	9.4	283
15	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.4	257
16	Novel genetic loci associated with hippocampal volume. Nature Communications, 2017, 8, 13624.	5.8	250
17	Multidomain lifestyle intervention benefits a large elderly population at risk for cognitive decline and dementia regardless of baseline characteristics: The FINGER trial. Alzheimer's and Dementia, 2018, 14, 263-270.	0.4	236
18	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. NeuroImage: Clinical, 2014, 6, 115-125.	1.4	233

#	Article	IF	CITATIONS
19	Novel genetic loci underlying human intracranial volume identified through genome-wide association. Nature Neuroscience, 2016, 19, 1569-1582.	7.1	213
20	CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings. Neurology, 2012, 78, 1568-1575.	1.5	208
21	Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology, 2000, 47, 470-476.	2.8	195
22	Genetic architecture of subcortical brain structures in 38,851 individuals. Nature Genetics, 2019, 51, 1624-1636.	9.4	192
23	Whole exome sequencing study identifies novel rare and common Alzheimer's-Associated variants involved in immune response and transcriptional regulation. Molecular Psychiatry, 2020, 25, 1859-1875.	4.1	191
24	Alzheimer's disease biomarker discovery using SOMAscan multiplexed protein technology. Alzheimer's and Dementia, 2014, 10, 724-734.	0.4	182
25	Future directions in Alzheimer's disease from risk factors to prevention. Biochemical Pharmacology, 2014, 88, 661-670.	2.0	181
26	Plasma proteins predict conversion to dementia from prodromal disease. Alzheimer's and Dementia, 2014, 10, 799.	0.4	180
27	Targeting Prodromal Alzheimer Disease With Avagacestat. JAMA Neurology, 2015, 72, 1324.	4.5	179
28	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. Lancet Neurology, The, 2017, 16, 965-975.	4.9	175
29	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 1145-1156.	0.4	174
30	Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 658-671.	0.4	173
31	Leisureâ€time physical activity from mid―to late life, body mass index, and risk of dementia. Alzheimer's and Dementia, 2015, 11, 434.	0.4	163
32	The EADCâ€ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. Alzheimer's and Dementia, 2015, 11, 111-125.	0.4	162
33	Remodeling of neuronal circuitries in human temporal lobe epilepsy: Increased expression of highly polysialylated neural cell adhesion molecule in the hippocampus and the entorhinal cortex. Annals of Neurology, 1998, 44, 923-934.	2.8	155
34	Heart Diseases and Long-Term Risk of Dementia and Alzheimer's Disease: A Population-Based CAIDE Study. Journal of Alzheimer's Disease, 2014, 42, 183-191.	1.2	155
35	Gene-Wide Analysis Detects Two New Susceptibility Genes for Alzheimer's Disease. PLoS ONE, 2014, 9, e94661.	1.1	155
36	Mixed Brain Pathologies in Dementia: The BrainNet Europe Consortium Experience. Dementia and Geriatric Cognitive Disorders, 2008, 26, 343-350.	0.7	148

#	Article	IF	CITATIONS
37	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
38	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	1.4	137
39	Effect of the Apolipoprotein E Genotype on Cognitive Change During a Multidomain Lifestyle Intervention. JAMA Neurology, 2018, 75, 462.	4.5	136
40	Association of Cerebral Amyloid-β Aggregation With Cognitive Functioning in Persons Without Dementia. JAMA Psychiatry, 2018, 75, 84.	6.0	133
41	Decreased hippocampal volume asymmetry on MRIs in nondemented elderly subjects carrying the apolipoprotein E ϵ4 allele. Neurology, 1995, 45, 391-392.	1.5	126
42	Modifiable Lifestyle Factors in Dementia: A Systematic Review of Longitudinal Observational Cohort Studies. Journal of Alzheimer's Disease, 2014, 42, 119-135.	1.2	125
43	Delphi definition of the EADCâ€ADNI Harmonized Protocol for hippocampal segmentation on magnetic resonance. Alzheimer's and Dementia, 2015, 11, 126-138.	0.4	123
44	Web-Based Interventions Targeting Cardiovascular Risk Factors in Middle-Aged and Older People: A Systematic Review and Meta-Analysis. Journal of Medical Internet Research, 2016, 18, e55.	2.1	116
45	The effect of increased genetic risk for Alzheimer's disease on hippocampal and amygdala volume. Neurobiology of Aging, 2016, 40, 68-77.	1.5	115
46	Mitochondrial DNA polymorphisms as risk factors for Parkinson?s disease and Parkinson?s disease dementia. Human Genetics, 2004, 115, 29-35.	1.8	113
47	Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia. Alzheimer's and Dementia, 2017, 13, 274-284.	0.4	113
48	Heterogeneous patterns of brain atrophy in Alzheimer's disease. Neurobiology of Aging, 2018, 65, 98-108.	1.5	110
49	Regional Distribution of α-Synuclein Pathology in Unimpaired Aging and Alzheimer Disease. Journal of Neuropathology and Experimental Neurology, 2003, 62, 363-367.	0.9	109
50	Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment. Alzheimer's and Dementia, 2017, 13, 285-295.	0.4	108
51	Circulating Proteomic Signatures of Chronological Age. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2015, 70, 809-816.	1.7	106
52	Plasma lipidomics analysis finds long chain cholesteryl esters to be associated with Alzheimer's disease. Translational Psychiatry, 2015, 5, e494-e494.	2.4	105
53	Validity of dementia and Alzheimer's disease diagnoses in Finnish national registers. Alzheimer's and Dementia, 2014, 10, 303-309.	0.4	103
54	Serum levels of vitamin E forms and risk of cognitive impairment in a Finnish cohort of older adults. Experimental Gerontology, 2013, 48, 1428-1435.	1.2	99

#	Article	IF	CITATIONS
55	Functional screening of Alzheimer risk loci identifies PTK2B as an in vivo modulator and early marker of Tau pathology. Molecular Psychiatry, 2017, 22, 874-883.	4.1	98
56	Postmenopausal hormone therapy and Alzheimer disease. Neurology, 2017, 88, 1062-1068.	1.5	98
57	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. JAMA Neurology, 2022, 79, 228.	4.5	97
58	Synaptic dysfunction and septin protein family members in neurodegenerative diseases. Molecular Neurodegeneration, 2015, 10, 16.	4.4	95
59	Cerebrospinal Fluid Biomarker and Brain Biopsy Findings in Idiopathic Normal Pressure Hydrocephalus. PLoS ONE, 2014, 9, e91974.	1.1	91
60	Practical cutâ€offs for visual rating scales of medial temporal, frontal and posterior atrophy in <scp>A</scp> lzheimer's disease and mild cognitive impairment. Journal of Internal Medicine, 2015, 278, 277-290.	2.7	91
61	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. Medical Image Analysis, 2020, 66, 101714.	7.0	90
62	Sleep disturbances and dementia risk: A multicenter study. Alzheimer's and Dementia, 2018, 14, 1235-1242.	0.4	85
63	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. Lancet Neurology, The, 2019, 18, 1034-1044.	4.9	85
64	Healthy ageing through internet counselling in the elderly (HATICE): a multinational, randomised controlled trial. The Lancet Digital Health, 2019, 1, e424-e434.	5.9	83
65	Effect of APOE Îμ4 Allele on Cortical Thicknesses and Volumes: The AddNeuroMed Study. Journal of Alzheimer's Disease, 2010, 21, 947-966.	1.2	82
66	36â€month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, 29-40.	0.4	77
67	Genetic Predisposition to Increased Blood Cholesterol and Triglyceride Lipid Levels and Risk of Alzheimer Disease: A Mendelian Randomization Analysis. PLoS Medicine, 2014, 11, e1001713.	3.9	75
68	Healthy Ageing Through Internet Counselling in the Elderly: the HATICE randomised controlled trial for the prevention of cardiovascular disease and cognitive impairment. BMJ Open, 2016, 6, e010806.	0.8	75
69	Brain volumes and cortical thickness on MRI in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's Research and Therapy, 2019, 11, 53.	3.0	75
70	Impaired mitochondrial energy metabolism in Alzheimer's disease: Impact on pathogenesis via disturbed epigenetic regulation of chromatin landscape. Progress in Neurobiology, 2015, 131, 1-20.	2.8	74
71	Association between Plasma Ceramides and Phosphatidylcholines and Hippocampal Brain Volume in Late Onset Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 60, 809-817.	1.2	72
72	Alzheimer's Diseaseâ€Associated Ubiquilinâ€1 Regulates Presenilinâ€1 Accumulation and Aggresome Formation. Traffic, 2011, 12, 330-348.	1.3	69

#	Article	IF	CITATIONS
73	Recruitment and Baseline Characteristics of Participants in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER)—A Randomized Controlled Lifestyle Trial. International Journal of Environmental Research and Public Health, 2014, 11, 9345-9360.	1.2	69
74	Automated Hippocampal Subfield Measures as Predictors of Conversion from Mild Cognitive Impairment to Alzheimer's Disease in Two Independent Cohorts. Brain Topography, 2015, 28, 746-759.	0.8	69
75	Adherence to multidomain interventions for dementia prevention: Data from the FINGER and MAPT trials. Alzheimer's and Dementia, 2019, 15, 729-741.	0.4	68
76	Dietary changes and cognition over 2 years within a multidomain intervention trial—The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2019, 15, 410-417.	0.4	63
77	Patient-specific Alzheimer-like pathology in trisomy 21 cerebral organoids reveals BACE2 as a gene dose-sensitive AD suppressor in human brain. Molecular Psychiatry, 2021, 26, 5766-5788.	4.1	63
78	The CAIDE Dementia Risk Score App: The development of an evidenceâ€based mobile application to predict the risk of dementia. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 328-333.	1.2	61
79	Metabolic phenotyping reveals a reduction in the bioavailability of serotonin and kynurenine pathway metabolites in both the urine and serum of individuals living with Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 20.	3.0	60
80	Prevalence of the apolipoprotein E ε4 allele in amyloid β positive subjects across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 913-924.	0.4	58
81	Cortical Brain Biopsy in Long-Term Prognostication of 468 Patients with Possible Normal Pressure Hydrocephalus. Neurodegenerative Diseases, 2012, 10, 166-169.	0.8	56
82	Transcriptomics and mechanistic elucidation of Alzheimer's disease risk genes in the brain and inÂvitro models. Neurobiology of Aging, 2015, 36, 1221.e15-1221.e28.	1.5	55
83	Computer-based cognitive training for older adults: Determinants of adherence. PLoS ONE, 2019, 14, e0219541.	1.1	52
84	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. Neurobiology of Aging, 2020, 95, 26-45.	1.5	51
85	High-fat diet increases tau expression in the brain of T2DM and AD mice independently of peripheral metabolic status. Journal of Nutritional Biochemistry, 2014, 25, 634-641.	1.9	50
86	Structural MRI in Frontotemporal Dementia: Comparisons between Hippocampal Volumetry, Tensor-Based Morphometry and Voxel-Based Morphometry. PLoS ONE, 2012, 7, e52531.	1.1	49
87	Effects of Alzheimer's Disease-Associated Risk Loci on Cerebrospinal Fluid Biomarkers and Disease Progression: A Polygenic Risk Score Approach. Journal of Alzheimer's Disease, 2014, 43, 565-573.	1.2	49
88	Meta-analysis of genome-wide DNA methylation identifies shared associations across neurodegenerative disorders. Genome Biology, 2021, 22, 90.	3.8	49
89	The Effect of a 2-Year Intervention Consisting of Diet, Physical Exercise, Cognitive Training, and Monitoring of Vascular Risk on Chronic Morbidity—the FINGER Randomized Controlled Trial. Journal of the American Medical Directors Association, 2018, 19, 355-360.e1.	1.2	48
90	Risk of Alzheimer's disease among users of postmenopausal hormone therapy: A nationwide case-control study. Maturitas, 2017, 98, 7-13.	1.0	47

#	Article	IF	CITATIONS
91	World Wide Fingers will advance dementia prevention. Lancet Neurology, The, 2018, 17, 27.	4.9	46
92	Predicting Progression of Alzheimer's Disease Using Ordinal Regression. PLoS ONE, 2014, 9, e105542.	1.1	44
93	Prognostic Polypeptide Blood Plasma Biomarkers of Alzheimer's Disease Progression. Journal of Alzheimer's Disease, 2014, 40, 659-666.	1.2	44
94	The Effect of Age Correction on Multivariate Classification in Alzheimer's Disease, with a Focus on the Characteristics of Incorrectly and Correctly Classified Subjects. Brain Topography, 2016, 29, 296-307.	0.8	44
95	Associations of CAIDE Dementia Risk Score with MRI, PIB-PET measures, andÂcognition. Journal of Alzheimer's Disease, 2017, 59, 695-705.	1.2	44
96	Cardiovascular health metrics from mid- to late-life and risk of dementia: A population-based cohort study in Finland. PLoS Medicine, 2020, 17, e1003474.	3.9	44
97	A Pathway Based Classification Method for Analyzing Gene Expression for Alzheimer's Disease Diagnosis. Journal of Alzheimer's Disease, 2015, 49, 659-669.	1.2	43
98	Cerebrovascular and amyloid pathology in predementia stages: the relationship with neurodegeneration and cognitive decline. Alzheimer's Research and Therapy, 2017, 9, 101.	3.0	43
99	Stability of graph theoretical measures in structural brain networks in Alzheimer's disease. Scientific Reports, 2018, 8, 11592.	1.6	41
100	A multiomic approach to characterize the temporal sequence in Alzheimer's disease-related pathology. Neurobiology of Disease, 2019, 124, 454-468.	2.1	41
101	Feasibility of radiological markers in idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2015, 157, 1709-1719.	0.9	40
102	Severity of Cardiovascular Disease, Apolipoprotein E Genotype, and Brain Pathology in Aging and Dementia. Annals of the New York Academy of Sciences, 2000, 903, 244-251.	1.8	39
103	Amyloid-β and Tau Dynamics in Human Brain Interstitial Fluid in Patients with Suspected Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2015, 46, 261-269.	1.2	39
104	Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Translational Psychiatry, 2015, 5, e584-e584.	2.4	39
105	Quantitative validation of a visual rating scale for frontal atrophy: associations with clinical status, APOE e4, CSF biomarkers and cognition. European Radiology, 2016, 26, 2597-2610.	2.3	39
106	Decreased plasma βâ€∎myloid in the Alzheimer's disease <scp><i>APP</i></scp> <scp>A</scp> 673 <scp>T</scp> variant carriers. Annals of Neurology, 2017, 82, 128-132.	2.8	39
107	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. Neurolmage: Clinical, 2017, 15, 613-624.	1.4	38
108	Caspase-8, association with Alzheimer's Disease and functional analysis of rare variants. PLoS ONE, 2017, 12, e0185777.	1.1	38

#	Article	IF	CITATIONS
109	Cardiorespiratory Fitness and Cognition: Longitudinal Associations in the FINGER Study. Journal of Alzheimer's Disease, 2019, 68, 961-968.	1.2	38
110	Incidence, Comorbidities, and Mortality in Idiopathic Normal PressureÂHydrocephalus. World Neurosurgery, 2018, 112, e624-e631.	0.7	37
111	The Association Between Distinct Frontal Brain Volumes and Behavioral Symptoms in Mild Cognitive Impairment, Alzheimer's Disease, and Frontotemporal Dementia. Frontiers in Neurology, 2019, 10, 1059.	1.1	37
112	Prediction models for dementia and neuropathology in the oldest old: the Vantaa 85+ cohort study. Alzheimer's Research and Therapy, 2019, 11, 11.	3.0	37
113	Midlife CAIDE Dementia Risk Score and Dementia-Related Brain Changes up to 30 Years Later on Magnetic Resonance Imaging. Journal of Alzheimer's Disease, 2015, 44, 93-101.	1.2	36
114	High Risk of Dementia in Ventricular Enlargement with Normal Pressure Hydrocephalus Related Symptoms1. Journal of Alzheimer's Disease, 2016, 52, 497-507.	1.2	36
115	The influence of insulin resistance on cerebrospinal fluid and plasma biomarkers of Alzheimer's pathology. Alzheimer's Research and Therapy, 2017, 9, 31.	3.0	36
116	Development and Validation of an Interactive Internet Platform for Older People: The Healthy Ageing Through Internet Counselling in the Elderly Study. Telemedicine Journal and E-Health, 2017, 23, 96-104.	1.6	36
117	A Multi-Cohort Study of ApoE ɛ4 and Amyloid-β Effects on the Hippocampus in Alzheimer's Disease. Journal of Alzheimer's Disease, 2017, 56, 1159-1174.	1.2	36
118	Designing an Internet-Based Multidomain Intervention for the Prevention of Cardiovascular Disease and Cognitive Impairment in Older Adults: The HATICE Trial. Journal of Alzheimer's Disease, 2018, 62, 649-663.	1.2	36
119	Longâ€ŧerm dementia risk prediction by the LIBRA score: A 30â€year followâ€up of the CAIDE study. International Journal of Geriatric Psychiatry, 2020, 35, 195-203.	1.3	36
120	CERAD Neuropsychological Compound Scores are Accurate in Detecting Prodromal Alzheimer's Disease: A Prospective AddNeuroMed Study. Journal of Alzheimer's Disease, 2014, 39, 679-690.	1.2	35
121	Detecting frontotemporal dementia syndromes using MRI biomarkers. NeuroImage: Clinical, 2019, 22, 101711.	1.4	35
122	The Effect of Multidomain Lifestyle Intervention on Daily Functioning in Older People. Journal of the American Geriatrics Society, 2019, 67, 1138-1144.	1.3	35
123	Age-Associated Memory Impairment. Drugs and Aging, 1997, 11, 480-489.	1.3	34
124	Midlife Work-Related Stress Increases Dementia Risk in Later Life: The CAIDE 30-Year Study. Journals of Gerontology - Series B Psychological Sciences and Social Sciences, 2017, 72, gbw043.	2.4	34
125	DHCR24 exerts neuroprotection upon inflammation-induced neuronal death. Journal of Neuroinflammation, 2017, 14, 215.	3.1	34
126	FASTKD2 is associated with memory and hippocampal structure in older adults. Molecular Psychiatry, 2015, 20, 1197-1204.	4.1	33

#	Article	IF	CITATIONS
127	Early psychosocial intervention does not delay institutionalization in persons with mild Alzheimer disease and has impact on neither disease progression nor caregivers' wellâ€being: ALSOVA 3â€year followâ€up. International Journal of Geriatric Psychiatry, 2016, 31, 273-283.	1.3	32
128	Predicting progression to dementia in persons with mild cognitive impairment using cerebrospinal fluid markers. Alzheimer's and Dementia, 2017, 13, 903-912.	0.4	32
129	Predicting AD Conversion: Comparison between Prodromal AD Guidelines and Computer Assisted PredictAD Tool. PLoS ONE, 2013, 8, e55246.	1.1	31
130	Generalizability of the Disease State Index Prediction Model for Identifying Patients Progressing from Mild Cognitive Impairment to Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 44, 79-92.	1.2	31
131	Nutrient intake and dietary changes during a 2-year multi-domain lifestyle intervention among older adults: secondary analysis of the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER) randomised controlled trial. British Journal of Nutrition, 2017, 118, 291-302.	1.2	31
132	Association of Rare <i>APOE</i> Missense Variants V236E and R251G With Risk of Alzheimer Disease. JAMA Neurology, 2022, 79, 652.	4.5	31
133	Oophorectomy, Hysterectomy, and Risk of Alzheimer's Disease: A Nationwide Case-Control Study. Journal of Alzheimer's Disease, 2014, 42, 575-581.	1.2	30
134	A Nutritional Approach to Ameliorate Altered Phospholipid Metabolism in Alzheimer's Disease. Journal of Alzheimer's Disease, 2014, 41, 715-717.	1.2	30
135	Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. Journal of Alzheimer's Disease, 2016, 49, 1105-1114.	1.2	30
136	Hospital admissions, outpatient visits and healthcare costs of communityâ€dwellers with Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 955-963.	0.4	30
137	Familial idiopathic normal pressure hydrocephalus. Journal of the Neurological Sciences, 2016, 368, 11-18.	0.3	30
138	Healthâ€related qualityâ€ofâ€life outcome in patients with idiopathic normalâ€pressure hydrocephalus – a 1â€year followâ€up study. European Journal of Neurology, 2017, 24, 58-66.	1.7	30
139	Melatonin receptor type 1A gene linked to Alzheimer's disease in old age. Sleep, 2018, 41, .	0.6	30
140	Urinary metabolic phenotyping for Alzheimer's disease. Scientific Reports, 2020, 10, 21745.	1.6	30
141	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	1.7	29
142	Altered Cerebrospinal Fluid Levels of Amyloid β and Amyloid Precursor-Like Protein 1 Peptides in Down's Syndrome. NeuroMolecular Medicine, 2014, 16, 510-516.	1.8	28
143	Risk prediction models in dementia prevention. Nature Reviews Neurology, 2015, 11, 375-377.	4.9	28
144	Predicting Development of Alzheimer's Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 71, 1233-1243.	1.2	28

#	Article	IF	CITATIONS
145	Older Adults' Reasons for Participating in an eHealth Prevention Trial: A Cross-Country, Mixed-Methods Comparison. Journal of the American Medical Directors Association, 2019, 20, 843-849.e5.	1.2	28
146	Experiences of dementia and attitude towards prevention: a qualitative study among older adults participating in a prevention trial. BMC Geriatrics, 2020, 20, 99.	1.1	28
147	Development of a Late-Life Dementia Prediction Index with Supervised Machine Learning in the Population-Based CAIDE Study. Journal of Alzheimer's Disease, 2016, 55, 1055-1067.	1.2	27
148	Relationship between ubiquilin-1 and BACE1 in human Alzheimer's disease and APdE9 transgenic mouse brain and cell-based models. Neurobiology of Disease, 2016, 85, 187-205.	2.1	27
149	The frequency and influence of dementia risk factors in prodromal Alzheimer's disease. Neurobiology of Aging, 2017, 56, 33-40.	1.5	27
150	Midlife work-related stress is associated with late-life cognition. Journal of Neurology, 2017, 264, 1996-2002.	1.8	27
151	Sleep disturbances and later cognitive status: a multi-centre study. Sleep Medicine, 2018, 52, 26-33.	0.8	27
152	Altered frontal and insular functional connectivity as pivotal mechanisms for apathy in Alzheimer's disease. Cortex, 2019, 119, 100-110.	1.1	27
153	The genetic architecture of human brainstem structures and their involvement in common brain disorders. Nature Communications, 2020, 11, 4016.	5.8	26
154	Effect of a multi-domain lifestyle intervention on cardiovascular risk in older people: the FINGER trial. European Heart Journal, 2022, 43, 2054-2061.	1.0	26
155	Modified serpinA1 as risk marker for Parkinson's disease dementia: Analysis of baseline data. Scientific Reports, 2016, 6, 26145.	1.6	24
156	Association Between Later Life Lifestyle Factors and Alzheimer's Disease Biomarkers in Non-Demented Individuals: A Longitudinal Descriptive Cohort Study. Journal of Alzheimer's Disease, 2017, 60, 1387-1395.	1.2	24
157	Cardiorespiratory fitness and risk of dementia: a prospective population-based cohort study. Age and Ageing, 2018, 47, 611-614.	0.7	24
158	Healthy Dietary Changes in Midlife Are Associated with Reduced Dementia Risk Later in Life. Nutrients, 2018, 10, 1649.	1.7	24
159	The effect of adherence on cognition in a multidomain lifestyle intervention (FINGER). Alzheimer's and Dementia, 2022, 18, 1325-1334.	0.4	24
160	Impact of a clinical decision support tool on prediction of progression in early-stage dementia: a prospective validation study. Alzheimer's Research and Therapy, 2019, 11, 25.	3.0	23
161	Automatically computed rating scales from MRI for patients with cognitive disorders. European Radiology, 2019, 29, 4937-4947.	2.3	23
162	Impact of a Clinical Decision Support Tool on Dementia Diagnostics in Memory Clinics: The PredictND Validation Study. Current Alzheimer Research, 2019, 16, 91-101.	0.7	23

#	Article	IF	CITATIONS
163	Quantifying dementia prevention potential in the FINGER randomized controlled trial using the LIBRA prevention index. Alzheimer's and Dementia, 2021, 17, 1205-1212.	0.4	23
164	Interleukin-18 alters protein expressions of neurodegenerative diseases-linked proteins in human SH-SY5Y neuron-like cells. Frontiers in Cellular Neuroscience, 2014, 8, 214.	1.8	22
165	Late-life cynical distrust, risk of incident dementia, and mortality in a population-based cohort. Neurology, 2014, 82, 2205-2212.	1.5	22
166	Predicting Progression from Cognitive Impairment to Alzheimer's Disease with the Disease State Index. Current Alzheimer Research, 2015, 12, 69-79.	0.7	22
167	Alzheimer's disease: a report from the 7th Kuopio Alzheimer symposium. Neurodegenerative Disease Management, 2015, 5, 379-382.	1.2	22
168	Factors Predicting Engagement of Older Adults With a Coach-Supported eHealth Intervention Promoting Lifestyle Change and Associations Between Engagement and Changes in Cardiovascular and Dementia Risk: Secondary Analysis of an 18-Month Multinational Randomized Controlled Trial. Journal of Medical Internet Research, 2022, 24, e32006.	2.1	22
169	Characteristics of subjective cognitive decline associated with amyloid positivity. Alzheimer's and Dementia, 2022, 18, 1832-1845.	0.4	22
170	Quantitative Evaluation of Disease Progression in a Longitudinal Mild Cognitive Impairment Cohort. Journal of Alzheimer's Disease, 2014, 39, 49-61.	1.2	21
171	Healthâ€related quality of life in patients with idiopathic normal pressure hydrocephalus. European Journal of Neurology, 2015, 22, 1391-1399.	1.7	21
172	Multimodal analysis to predict shunt surgery outcome of 284 patients with suspected idiopathic normal pressure hydrocephalus. Acta Neurochirurgica, 2016, 158, 2311-2319.	0.9	21
173	Differential Associations of IL-4 With Hippocampal Subfields in Mild Cognitive Impairment and Alzheimer's Disease. Frontiers in Aging Neuroscience, 2018, 10, 439.	1.7	21
174	Feelings of Hopelessness in Midlife and Cognitive Health in Later Life: A Prospective Population-Based Cohort Study. PLoS ONE, 2015, 10, e0140261.	1.1	21
175	The interactive effect of demographic and clinical factors on hippocampal volume: A multicohort study on 1958 cognitively normal individuals. Hippocampus, 2017, 27, 653-667.	0.9	20
176	Baseline Telomere Length and Effects of a Multidomain Lifestyle Intervention on Cognition: The FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2017, 59, 1459-1470.	1.2	20
177	The Expression of Transthyretin and Amyloid-β Protein Precursor is Altered in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2015, 48, 959-968.	1.2	19
178	Genetic risk factors in Finnish patients with Parkinson's disease. Parkinsonism and Related Disorders, 2017, 45, 39-43.	1.1	19
179	Automatic MRI Quantifying Methods in Behavioral-Variant Frontotemporal Dementia Diagnosis. Dementia and Geriatric Cognitive Disorders Extra, 2018, 8, 51-59.	0.6	19
180	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	1.2	19

#	Article	IF	CITATIONS
181	Dementia risk scores as surrogate outcomes for lifestyleâ€based multidomain prevention trials—rationale, preliminary evidence and challenges. Alzheimer's and Dementia, 2020, 16, 1674-1685.	0.4	18
182	27-Hydroxycholesterol, cognition, and brain imaging markers in the FINGER randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 56.	3.0	18
183	Tolerability of ORMâ€12741 and effects on episodic memory in patients with Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 1-9.	1.8	17
184	Epilepsy in neuropathologically verified Alzheimer's disease. Seizure: the Journal of the British Epilepsy Association, 2018, 58, 9-12.	0.9	17
185	White Matter Changes on Diffusion Tensor Imaging in the FINGER Randomized Controlled Trial. Journal of Alzheimer's Disease, 2020, 78, 75-86.	1.2	17
186	Association of Peripheral Insulin Resistance and Other Markers of Type 2 Diabetes Mellitus with Brain Amyloid Deposition in Healthy Individuals at Risk of Dementia. Journal of Alzheimer's Disease, 2020, 76, 1243-1248.	1.2	17
187	Change in CAIDE Dementia Risk Score and Neuroimaging Biomarkers During a 2-Year Multidomain Lifestyle Randomized Controlled Trial: Results of a Post-Hoc Subgroup Analysis. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 1407-1414.	1.7	17
188	Automatic temporal lobe atrophy assessment in prodromal AD: Data from the DESCRIPA study. Alzheimer's and Dementia, 2014, 10, 456-467.	0.4	16
189	Genetic Variation in δ-Opioid Receptor Associates with Increased β- and γ-Secretase Activity in the Late Stages of Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 48, 507-516.	1.2	16
190	Effect of a Multidomain Lifestyle Intervention on Estimated Dementia Risk. Journal of Alzheimer's Disease, 2021, 82, 1461-1466.	1.2	16
191	SEPT8 modulates Î ² -amyloidogenic processing of APP via affecting the sorting and accumulation of BACE1. Journal of Cell Science, 2016, 129, 2224-38.	1.2	15
192	Prevalence of Schizophrenia in Idiopathic Normal Pressure Hydrocephalus. Neurosurgery, 2019, 84, 883-889.	0.6	15
193	Software Tool for Improved Prediction of Alzheimer's Disease. Neurodegenerative Diseases, 2012, 10, 149-152.	0.8	14
194	Copy number loss in SFMBT1 is common among Finnish and Norwegian patients with iNPH. Neurology: Genetics, 2018, 4, e291.	0.9	14
195	Targeted Serum Metabolite Profiling Identifies Metabolic Signatures in Patients with Alzheimer's Disease, Normal Pressure Hydrocephalus and Brain Tumor. Frontiers in Neuroscience, 2017, 11, 747.	1.4	14
196	Serum Insulin and Cognitive Performance in Older Adults: A Longitudinal Study. American Journal of Medicine, 2019, 132, 367-373.	0.6	14
197	Coronary Heart Disease and Cortical Thickness, Gray Matter and White Matter Lesion Volumes on MRI. PLoS ONE, 2014, 9, e109250.	1.1	14
198	Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients. Journal of Alzheimer's Disease, 2019, 72, 127-137.	1.2	13

#	Article	IF	CITATIONS
199	[11C]PIB PET Is Associated with the Brain Biopsy Amyloid-β Load in Subjects Examined for Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2019, 67, 1343-1351.	1.2	13
200	Gait Disturbances are Associated with Increased Cognitive Impairment and Cerebrospinal Fluid Tau Levels in a Memory Clinic Cohort. Journal of Alzheimer's Disease, 2020, 76, 1061-1070.	1.2	13
201	Metabolic Profiles Help Discriminate Mild Cognitive Impairment from Dementia Stage in Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 74, 277-286.	1.2	13
202	Using the Disease State Fingerprint Tool for Differential Diagnosis of Frontotemporal Dementia and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2016, 6, 313-329.	0.6	12
203	The Modified Frontal Behavioral Inventory (FBI-mod) for Patients with Frontotemporal Lobar Degeneration, Alzheimer's Disease, and Mild Cognitive Impairment. Journal of Alzheimer's Disease, 2017, 56, 1241-1251.	1.2	12
204	Quantitative Genetics Validates Previous Genetic Variants and Identifies Novel Genetic Players Influencing Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2018, 66, 639-652.	1.2	12
205	Increased Î ³ -Secretase Activity in Idiopathic Normal Pressure Hydrocephalus Patients with Î ² -Amyloid Pathology. PLoS ONE, 2014, 9, e93717.	1.1	12
206	Cardiorespiratory fitness and brain volumes in men and women in the FINGER study. Age and Ageing, 2017, 46, 310-313.	0.7	11
207	Associations between Prospective and Retrospective Subjective Memory Complaints and Neuropsychological Performance in Older Adults: The Finger Study. Journal of the International Neuropsychological Society, 2018, 24, 1099-1109.	1.2	11
208	Understanding the effect of cognitive/brain reserve and depression on regional atrophy in early Alzheimer's disease. Postgraduate Medicine, 2019, 131, 533-538.	0.9	11
209	Telomere Length Change in a Multidomain Lifestyle Intervention to Prevent Cognitive Decline: A Randomized Clinical Trial. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2021, 76, 491-498.	1.7	11
210	Obesity and Brain Vulnerability in Normal and Abnormal Aging: A Multimodal MRI Study. Journal of Alzheimer's Disease Reports, 2021, 5, 65-77.	1.2	11
211	Linking Genetics of Brain Changes to Alzheimer's Disease: Sparse Whole Genome Association Scan of Regional MRI Volumes in the ADNI and AddNeuroMed Cohorts. Journal of Alzheimer's Disease, 2015, 45, 851-864.	1.2	10
212	Improved Cerebrospinal Fluid-Based Discrimination between Alzheimer's Disease Patients and Controls after Correction for Ventricular Volumes. Journal of Alzheimer's Disease, 2017, 56, 543-555.	1.2	10
213	Estradiol and Cognition in the Cardiovascular Risk Factors, Aging andÂDementia (CAIDE) Cohort Study. Journal of Alzheimer's Disease, 2017, 56, 453-458.	1.2	10
214	Integrating nurses' experiences with supporting behaviour change for cardiovascular prevention into a self-management internet platform in Finland and the Netherlands: a qualitative study. BMJ Open, 2019, 9, e023480.	0.8	10
215	Brain β-Amyloid and Atrophy in Individuals at Increased Risk of Cognitive Decline. American Journal of Neuroradiology, 2019, 40, 80-85.	1.2	10
216	Vascular risk factors, ApoE ?4 allele, and gender and the risk of Alzheimer's disease: perspectives on prevention. Drug Development Research, 2002, 56, 85-94.	1.4	9

#	Article	IF	CITATIONS
217	Alleles that increase risk for type 2 diabetes mellitus are not associated with increased risk for Alzheimer's disease. Neurobiology of Aging, 2014, 35, 2883.e3-2883.e10.	1.5	9
218	Subtle Cognitive Impairment and Alzheimer's Disease-Type Pathological Changes in Cerebrospinal Fluid are Common Among Neurologically Healthy Subjects. Journal of Alzheimer's Disease, 2018, 62, 165-174.	1.2	9
219	Prevalence of <i>C9ORF72</i> Expansion in a Large Series of Patients with Idiopathic Normal-Pressure Hydrocephalus. Dementia and Geriatric Cognitive Disorders, 2019, 47, 91-103.	0.7	9
220	Detecting Amyloid Positivity in Elderly With Increased Risk of Cognitive Decline. Frontiers in Aging Neuroscience, 2020, 12, 228.	1.7	9
221	Alzheimer's diseaseâ€related plaques in nondemented subjects. Alzheimer's and Dementia, 2014, 10, 522-529.	0.4	8
222	Alzheimer's Disease-Related Polymorphisms in Shunt-Responsive Idiopathic Normal Pressure Hydrocephalus. Journal of Alzheimer's Disease, 2017, 60, 1077-1085.	1.2	8
223	Third follow-up of the Cardiovascular Risk Factors, Aging and Dementia (CAIDE) cohort investigating determinants of cognitive, physical, and psychosocial wellbeing among the oldest old: the CAIDE85+ study protocol. BMC Geriatrics, 2020, 20, 238.	1.1	8
224	Presynaptic Vesicle Protein SEPTIN5 Regulates the Degradation of APP C-Terminal Fragments and the Levels of Aî ² . Cells, 2020, 9, 2482.	1.8	8
225	Regional Strength of Large-Scale Functional Brain Networks is Associated with Regional Volumes in Older Adults and in Alzheimer's Disease. Brain Connectivity, 2021, 11, 201-212.	0.8	8
226	CERAD Neuropsychological Total Scores Reflect Cortical Thinning in Prodromal Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2013, 3, 446-458.	0.6	7
227	Effects of morphological family on word recognition in normal aging, mild cognitive impairment, and Alzheimer's disease. Cortex, 2019, 116, 91-103.	1.1	7
228	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimer's Disease Pathology. Journal of Alzheimer's Disease, 2020, 77, 1353-1368.	1.2	7
229	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. PLoS ONE, 2020, 15, e0226784.	1.1	7
230	Earlier life leisure-time physical activity in relation to age-related frailty syndrome. Age and Ageing, 2021, 50, 161-168.	0.7	7
231	Tacrine may alter APP-like protein levels in the lumbar CSF of Alzheimer patients. International Journal of Geriatric Psychiatry, 2001, 16, 1104-1106.	1.3	6
232	Involvement of ubiquilin-1 transcript variants in protein degradation and accumulation. Communicative and Integrative Biology, 2011, 4, 428-432.	0.6	6
233	Effects of Alzheimer's Disease-Associated Risk Loci on Amyloid-β Accumulation in the Brain of Idiopathic Normal Pressure Hydrocephalus Patients. Journal of Alzheimer's Disease, 2016, 55, 995-1003.	1.2	6
234	Diabetes is associated with familial idiopathic normal pressure hydrocephalus: a case–control comparison with family members. Fluids and Barriers of the CNS, 2020, 17, 57.	2.4	6

#	Article	IF	CITATIONS
235	Research diagnostic criteria for Alzheimer's disease: findings from the LipiDiDiet randomized controlled trial. Alzheimer's Research and Therapy, 2021, 13, 64.	3.0	6
236	Behavioural and ERP effects of paradigm complexity on visual word recognition. Language, Cognition and Neuroscience, 2014, 29, 1295-1310.	0.7	5
237	O3â€05â€05: EFFECTS OF A MULTIDOMAIN LIFESTYLE INTERVENTION ON OVERALL RISK FOR DEMENTIA: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2018, 14, P1024.	0.4	5
238	Using joint models to disentangle intervention effect types and baseline confounding: an application within an intervention study in prodromal Alzheimer's disease with Fortasyn Connect. BMC Medical Research Methodology, 2019, 19, 163.	1.4	5
239	Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change. Journal of Alzheimer's Disease, 2019, 71, 785-795.	1.2	5
240	Lateâ€life personality traits, cognitive impairment, and mortality in a populationâ€based cohort. International Journal of Geriatric Psychiatry, 2020, 35, 989-999.	1.3	5
241	White Matter Hyperintensities Are No Major Confounder for Alzheimer's Disease Cerebrospinal Fluid Biomarkers. Journal of Alzheimer's Disease, 2021, 79, 163-175.	1.2	5
242	5-Year health-related quality of life outcome in patients with idiopathic normal pressure hydrocephalus. Journal of Neurology, 2021, 268, 3283-3293.	1.8	5
243	Psychosocial determinants for adherence to a healthy lifestyle and intervention participation in the FINGER trial: an exploratory analysis of a randomised clinical trial. Aging Clinical and Experimental Research, 2022, 34, 1793-1805.	1.4	5
244	Why Does the Health-Related Quality of Life in Idiopathic Normal-Pressure Hydrocephalus Fail to Improve Despite the Favorable Clinical Outcome?. World Neurosurgery, 2017, 108, 356-366.	0.7	4
245	Biomarker validation of a dementia risk prediction score. Nature Reviews Neurology, 2020, 16, 135-136.	4.9	4
246	Attitudes of at-risk older adults about prevention of cardiovascular disease and dementia using eHealth: a qualitative study in a European context. BMJ Open, 2020, 10, e037050.	0.8	4
247	S327 phosphorylation of the presynaptic protein SEPTIN5 increases in the early stages of neurofibrillary pathology and alters the functionality of SEPTIN5. Neurobiology of Disease, 2022, 163, 105603.	2.1	4
248	Occupational complexity and cognition in the FINGER multidomain intervention trial. Alzheimer's and Dementia, 2022, 18, 2438-2447.	0.4	4
249	P4â€392: Healthy Ageing Through Internet Counselling in the Elderly (HATICE): an Ongoing Randomised Controlled Trial. Alzheimer's and Dementia, 2016, 12, P1187.	0.4	3
250	Improving data sharing in research with context-free encoded missing data. PLoS ONE, 2017, 12, e0182362.	1.1	3
251	Interrelationship between the Levels of C9orf72 and Amyloid-β Protein Precursor and Amyloid-β in Human CellsÂand Brain Samples. Journal of Alzheimer's Disease, 2018, 62, 269-278.	1.2	3
252	Midlife improvements in financial situation are associated with a reduced dementia risk later in life: the CAIDE 30-year study. International Psychogeriatrics, 2020, 32, 1317-1324.	0.6	3

#	Article	IF	CITATIONS
253	A competing risk joint model for dealing with different types of missing data in an intervention trial in prodromal Alzheimer's disease. Alzheimer's Research and Therapy, 2021, 13, 63.	3.0	3
254	No Evidence to Suggest that the Use of Acetylcholinesterase Inhibitors Confounds the Results of Two Blood-Based Biomarker Studies in Alzheimer's Disease. Journal of Alzheimer's Disease, 2015, 47, 741-750.	1.2	2
255	DTâ€01â€04: Effects of Fortasyn Connect (Souvenaid) on Longitudinal Brain Atrophy Measures in Prodromal Alzheimer's Disease: Results of the Doubleâ€Blind Randomised Controlled Lipididiet Trial. Alzheimer's and Dementia, 2016, 12, P1135.	0.4	2
256	Midlife Work-Related Stress is Associated with Late-Life Gray Matter Volume Atrophy. Journal of Alzheimer's Disease Reports, 2017, 1, 219-227.	1.2	2
257	Production of Inflected Novel Words in Older Adults With and Without Dementia. Cognitive Science, 2020, 44, e12879.	0.8	2
258	Pooling individual participant data from randomized controlled trials: Exploring potential loss of information. PLoS ONE, 2020, 15, e0232970.	1.1	2
259	Verbal fluency activates the left medial temporal lobe: A functional magnetic resonance imaging study. Annals of Neurology, 2000, 47, 470-476.	2.8	2
260	Response to letter by Bullock and Truyen. International Journal of Geriatric Psychiatry, 2005, 20, 87-89.	1.3	1
261	Hippocampal atrophy rate using an expectation maximization classifier with a disease-specific prior. , 2012, , .		1
262	[P1–616]: DIETARY INTERVENTION ADHERENCE AND COGNITIVE CHANGES AMONG INDIVIDUALS WITH ELEVATED RISK OF DEMENTIA: THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P532.	0.4	1
263	[P3–573]: HEALTHY AGEING THROUGH INTERNET COUNSELLING IN THE ELDERLY (HATICE): AN ONGOING RANDOMISED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1198.	0.4	1
264	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. Alzheimer's and Dementia, 2020, 16, e041808.	0.4	1
265	Effect of berries and fruits on cognitive change during a 2â€year multiâ€domain lifestyle intervention: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2020, 16, e042431.	0.4	1
266	Associations of Depressive Symptoms and Cognition in the FINGER Trial: A Secondary Analysis of a Randomised Clinical Trial. Journal of Clinical Medicine, 2022, 11, 1449.	1.0	1
267	O2-02-01: Prediction of Alzheimer's disease by beta-amyloid plaques and tau protein in frontal cortical biopsy. , 2010, 6, S97-S97.		0
268	O1-01-01: Cerebrospinal fluid biomarkers for Alzheimer's disease are associated with neuropathology in cortical brain biopsy. , 2012, 8, P83-P84.		0
269	P4-351: A PLASMA PHOSPHOLIPID BIOMARKER PROFILE FOR DETECTING PRECLINICAL ALZHEIMER'S DISEASE CAN BE MODIFIED BY ORAL INTAKE OF NUTRIENTS THAT INCREASE PHOSPHOLIPID SYNTHESIS. , 2014, 10, P916-P917.		0
270	P3-030: White Matter Changes on Diffusion Tensor Imaging in the Finnish Geriatric Intervention Study		0

to Prevent Cognitive Impairment and Disability (FINGER). , 2016, 12, P828-P828.

#	Article	IF	CITATIONS
271	P1-069: Influence of Apoe, Age, Sex, Education and Baseline Cognition on Intervention Effects on Cognition in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). , 2016, 12, P428-P429.		0
272	[P1–019]: MULTIDOMAIN LIFESTYLE INTERVENTION BENEFITS A LARGE ELDERLY POPULATION AT RISK FOR COGNITIVE DECLINE: SUBGROUP ANALYSES OF THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P239.	0.4	0
273	[P1–573]: SERUM INSULIN AND THE RISK OF DEMENTIA AND COGNITIVE DECLINE: A LONGITUDINAL POPULATIONâ€BASED STUDY. Alzheimer's and Dementia, 2017, 13, P514.	0.4	0
274	[P1–009]: DETECTING COGNITIVE DISORDERS USING THE MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P234.		0
275	[P1–071]: MULTIDOMAIN LIFESTYLE INTERVENTION BENEFITS A LARGE ELDERLY POPULATION AT RISK FOR COGNITIVE DECLINE: SUBGROUP ANALYSES OF THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P265.	0.4	0
276	[P3–464]: WAISTâ€TOâ€HIP RATIO RELATED GREY MATTER REDUCTIONS IN ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P1151.	⁵ 0.4	0
277	[P3–549]: MIDLIFE COFFEE DRINKING AND DEMENTIAâ€RELATED BRAIN CHANGES ON MRI UP TO 28 YEARS LATER. Alzheimer's and Dementia, 2017, 13, P1188.	0.4	0
278	[P3–572]: MULTIMODAL LIFESTYLE AND NUTRITIONAL INTERVENTION IN PRODROMAL ALZHEIMER'S DISEASE: MINDâ€AD _{MINI} PILOT TRIAL. Alzheimer's and Dementia, 2017, 13, P1198.	0.4	0
279	[P3–574]: ASSOCIATIONS OF LEUCOCYTE TELOMERE LENGTH WITH BRAINÂMRIÂAND PIBâ€PET MEASURES: THEÂFINGER STUDY. Alzheimer's and Dementia, 2017, 13, P1199.	0.4	0
280	[P3–579]: IMPACT OF BASELINE BRAIN MRI MEASURES ON COGNITIVE EFFECTS OF A MULTIDOMAIN INTERVENTION: THE FINGER RANDOMIZED CONTROLLED TRIAL. Alzheimer's and Dementia, 2017, 13, P1202.	0.4	0
281	[P3–581]: THE IMPACT OF ADHERENCE TO MULTIDOMAIN LIFESTYLE INTERVENTION ON COGNITION: THE FINNISH GERIATRIC INTERVENTION STUDY TO PREVENT COGNITIVE IMPAIRMENT AND DISABILITY (FINGER). Alzheimer's and Dementia, 2017, 13, P1203.	0.4	0
282	[P1–326]: DETECTING COGNITIVE DISORDERS USING MUISTIKKO WEBâ€BASED COGNITIVE TEST BATTERY: VALIDATION IN THREE COHORTS. Alzheimer's and Dementia, 2017, 13, P380.	0.4	0
283	P1â€⊋51: CSFâ€NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER'S DISEASE SPECIFIC BIOMARKER. Alzheimer's and Dementia, 2018, 14, P376.	^{\$} 0.4	0
284	The impact of a nutritional intervention in prodromal Alzheimer's disease: The LipiDiDiet clinical trial. Alzheimer's and Dementia, 2020, 16, e039846.	0.4	0
285	Gait disturbances are associated with increased CSF tau levels in a memory clinic cohort. Alzheimer's and Dementia, 2020, 16, e040152.	0.4	Ο
286	Change in CAIDE dementia risk score and neuroimaging biomarkers during a 2â€year multidomain lifestyle randomized controlled trial. Alzheimer's and Dementia, 2020, 16, e040879.	0.4	0
287	Impact of baseline impaired sleep, depressive symptoms and pain on physical activity in the FINGER multidomain lifestyle trial. Alzheimer's and Dementia, 2020, 16, e041462.	0.4	Ο
288	Research diagnostic criteria for Alzheimer's disease: Findings from the multinational LipiDiDiet Trial. Alzheimer's and Dementia, 2020, 16, e042530.	0.4	0

#	Article	IF	CITATIONS
289	Differential diagnosis of dementia combining webâ€based cognitive testing and MRI. Alzheimer's and Dementia, 2020, 16, e042626.	0.4	Ο
290	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. Alzheimer's and Dementia, 2020, 16, e042687.	0.4	0
291	Suitability of dementia risk scores as surrogate outcomes for lifestyleâ€based multidomain prevention trials. Alzheimer's and Dementia, 2020, 16, e042798.	0.4	Ο
292	Longâ€ŧerm dietary intervention adherence among individuals with elevated risk of dementia: The Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2020, 16, e045150.	0.4	0
293	The reliability of a deep learning model in external memory clinic MRI data: A multi ohort study. Alzheimer's and Dementia, 2020, 16, e042969.	0.4	0
294	The association between diabetes and Alzheimer's disease pathophysiology. Alzheimer's and Dementia, 2021, 17, .	0.4	0
295	Multimodal preventive trial for Alzheimer's disease (MINDâ€AD _{MINI}): Pilot trial progress and results. Alzheimer's and Dementia, 2021, 17, .	0.4	0
296	Occupational complexity and neuroimaging measures of structural MRI and PETâ€amyloid in a randomized controlled trial: FINGER. Alzheimer's and Dementia, 2021, 17, .	0.4	0
297	Lifestyle and behavior changes during the COVID19 pandemic in the Finnish Geriatric Intervention Study to Prevent Cognitive Impairment and Disability (FINGER). Alzheimer's and Dementia, 2021, 17, .	0.4	0
298	Engagement with a preventive eHealth intervention in older adults (the HATICE trial): Predictive factors and associations with dementia and cardiovascular risk. Alzheimer's and Dementia, 2021, 17, .	0.4	0
299	Title is missing!. , 2020, 17, e1003474.		Ο
300	Title is missing!. , 2020, 17, e1003474.		0
301	Title is missing!. , 2020, 17, e1003474.		Ο
302	Title is missing!. , 2020, 17, e1003474.		0
303	Title is missing!. , 2020, 17, e1003474.		0
304	Title is missing!. , 2020, 17, e1003474.		0
305	Title is missing!. , 2020, 17, e1003474.		0
306	Title is missing!. , 2020, 15, e0226784.		0

#	Article	IF	CITATIONS
307	Title is missing!. , 2020, 15, e0226784.		0
308	Title is missing!. , 2020, 15, e0226784.		0
309	Title is missing!. , 2020, 15, e0226784.		0